in vitro sensitivity-directed chemotherapy

Phase 3Small molecule

in vitro sensitivity-directed chemotherapy is one of 104 small molecule programs targeting Leukemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

103

Competitors

Pipeline

Status by Indication[3][1]

Indication

LeukemiaActive, not recruiting

Ovarian CancerActive, not recruiting

Acute LeukemiaActive, not recruiting

LeukemiaPreclinical

Active, not recruiting

Ovarian CancerPhase 3

Active, not recruiting

Acute LeukemiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

836 competitors in Ovarian Cancer

#DrugCompanyPhaseTrials

Hycamtin

MMeitheal

Phase 3

28 2

Cytoxan

BBaxter Healthcare Corporation

Phase 3

21 3

Aromasin

Pfizer

Phase 3

2 4

Vepesid

AAvyxa

Phase 3

6 5

Chemotherapy Drug

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3

1 6

AZD5335

AstraZeneca

Phase 3

1 7

in vitro sensitivity-directed chemotherapy

CChildren's Oncology Group

Phase 3

1 8

Fluzoparib; Apatinib

JJiangsu HengRui Medicine Co., Ltd.

Phase 3

1 9

Gleolan

NNX Development Corp

Phase 3

1 10

Standard Single Agent Chemotherapy

FFondazione Policlinico Universitario Agostino Gemelli IRCCS

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Acute Leukemia1 trial

High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia

Completed·UUniversity of Washington·N/A·NCT02551718·34 enrolled

Ovarian Cancer1 trial

Chemosensitivity Testing to Assign Treatment for Patients With Stage III or Stage IV Ovarian Cancer

Completed·SSwiss Cancer Institute·Phase 3·NCT00003214·300 enrolled

Leukemia1 trial

Cell Samples From Patients With Leukemia

Completed·CChildren's Oncology Group··NCT01395628·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for in vitro sensitivity-directed chemotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — in vitro sensitivity-directed chemotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for in vitro sensitivity-directed chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Children's Oncology Group company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CChildren's Oncology Group

in vitro sensitivity-directed chemotherapy

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Acute Leukemia1 trial

Ovarian Cancer1 trial

Leukemia1 trial

References

Drug Info

Quick Facts

Related News